摘要
目的观察锶(89Sr)联合锝(99Tc-MDP)治疗肺癌骨转移临床疗效。方法将63例肺癌骨转移患者随机分为实验组(30例)与对照组(33例)。实验组应用89Sr联合99Tc-MDP治疗,对照组应用89Sr治疗。随访3个月,主要观察两组患者治疗前后的疼痛、生活质量、血象、骨显像所示骨转移灶数目的改善情况。计数资料采用卡方检验。结果经统计分析,实验组与对照组的止痛有效率分别为80.00%与54.54%;实验组与对照组治疗后骨痛缓解有效率(χ2=4.582)、生活质量改善率(83.33%与57.58%,χ2=4.950)和骨转移病灶治疗有效率(83.33%与60.61%,χ2=3.977)间比较差异有统计学意义(P均<0.05),而毒副反应实验组没有明显叠加(χ2=1.880,P>0.05)。结论89Sr联合99Tc-MDP的治疗方法较单独使用89Sr能显著提高肺癌骨转移疼痛的临床疗效。
Objective To evaluate the palliative effect on pain relief in patients of lung cancer with bone metastasis treated with strontium-89 combined with 99Tc-MDP and strontium-89 alone.Methods 63 patients of lung cancer with bone metastasis were divided into experimental group and control group randomly.33 patients in the control group were treated with strontium-89 only,30 patients in the experimental group were treated with 89Sr combined with 99Tc-MDP.The improvement on patients' pain,quality of life,blood,the number of bone metastases was mainly observed before and after treatment.The χ2 test was used for data analysis.Results The overall palliative pain relief rate in the experimental treatment group and control group were 80.00% and 54.54%,respectively.There are statistically significant differences between two groups in the overall palliative pain relief rate(χ2=4.582),in terms of improvement in quality of life score(83.33% to 57.58%,χ2=4.950),and focal palliative rate(83.33% to 60.61%,χ2=3.977).The side-effect in two groups were not increased obviously(χ2=1.880,P0.05).Conclusion The combined 89Sr with 99Tc-MDP in the treatment for pain relief in patients of lung cancer with bone metastasis is much more effective than single treatment and could improve the efficacy significantly.
出处
《标记免疫分析与临床》
CAS
2012年第4期197-200,共4页
Labeled Immunoassays and Clinical Medicine